CA3199088A1 - Respiratory treatments - Google Patents

Respiratory treatments

Info

Publication number
CA3199088A1
CA3199088A1 CA3199088A CA3199088A CA3199088A1 CA 3199088 A1 CA3199088 A1 CA 3199088A1 CA 3199088 A CA3199088 A CA 3199088A CA 3199088 A CA3199088 A CA 3199088A CA 3199088 A1 CA3199088 A1 CA 3199088A1
Authority
CA
Canada
Prior art keywords
lipopeptide
salt
foregoing
optionally substituted
isomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3199088A
Other languages
English (en)
French (fr)
Inventor
Bomi FRAMROZE
Crawford Linden Alexander CURRIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3199088A1 publication Critical patent/CA3199088A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3199088A 2020-11-17 2021-11-15 Respiratory treatments Pending CA3199088A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063114976P 2020-11-17 2020-11-17
US63/114,976 2020-11-17
US202163211972P 2021-06-17 2021-06-17
US63/211,972 2021-06-17
PCT/US2021/059416 WO2022108883A1 (en) 2020-11-17 2021-11-15 Respiratory treatments

Publications (1)

Publication Number Publication Date
CA3199088A1 true CA3199088A1 (en) 2022-05-27

Family

ID=81709617

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3199088A Pending CA3199088A1 (en) 2020-11-17 2021-11-15 Respiratory treatments

Country Status (9)

Country Link
US (1) US20240002436A1 (https=)
EP (1) EP4247165A4 (https=)
JP (1) JP2023549855A (https=)
KR (1) KR20230110295A (https=)
AU (1) AU2021383599A1 (https=)
CA (1) CA3199088A1 (https=)
MX (1) MX2023005663A (https=)
TW (1) TW202233647A (https=)
WO (1) WO2022108883A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025101524A1 (en) * 2023-11-06 2025-05-15 Hbc Immunology Inc. Lipopeptide compounds, and use in modulating eosinophilia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546164B1 (fr) * 1983-05-16 1987-07-17 Centre Nat Rech Scient Nouveaux derives de peptides, leur preparation et leur application comme inhibiteurs de l'elastase
JPH0611754B2 (ja) * 1985-10-09 1994-02-16 サントリー株式会社 ペプチダ−ゼ阻害作用を有する新規化合物及びその製法並びに用途
EP0201743B1 (en) * 1985-04-16 1992-04-01 Suntory Limited Dipeptide derivatives of fatty acids, process for preparing them, pharmaceutical composition and use
AU2003250586B2 (en) * 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
WO2009046220A2 (en) * 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
KR101250812B1 (ko) * 2011-03-18 2013-04-04 미원상사주식회사 언데세노일 디펩타이드 유도체 및 이를 함유하는 피부미백용 화장료 조성물
US20140154257A1 (en) * 2012-06-07 2014-06-05 Luanne Robalo DeChristopher Materials and methods for diagnosing and treating asthma and dietary Fru-AGEs related disorders including auto-immune and other diseases found to be associated with elevated RAGE. The specification describes methods to identify and make dietary derived advanced glycation end-products, known as Fru-AGEs, Fru-AGE-haptens, and Fru-AGE immune complexes, and to make monoclonal and polyclonal antibodies to this plurality of bio-molecules for use in immunoassays and for use as therapeutic agents
US9371276B1 (en) * 2015-03-21 2016-06-21 Mohan Murali Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
WO2017068477A1 (en) * 2015-10-18 2017-04-27 Rao M Surya Compound, composition and uses thereof

Also Published As

Publication number Publication date
WO2022108883A1 (en) 2022-05-27
US20240002436A1 (en) 2024-01-04
AU2021383599A1 (en) 2023-05-25
KR20230110295A (ko) 2023-07-21
EP4247165A4 (en) 2025-01-22
AU2021383599A9 (en) 2024-02-08
MX2023005663A (es) 2023-05-26
EP4247165A1 (en) 2023-09-27
JP2023549855A (ja) 2023-11-29
TW202233647A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
CN116761599B (zh) 氘代或部分氘代的n,n-二甲基色胺化合物
CN103191410B (zh) T-细胞介导的疾病的治疗
JP7482532B2 (ja) サイクロセリン化合物の製剤およびそれらの用途
EA013973B1 (ru) Способы лечения кожной волчанки при помощи аминоизоиндолиновых соединений
US20020107176A1 (en) Brain targeted low molecular weight hydrophobic anti oxidant compounds
WO2011156003A2 (en) Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
US20260102392A1 (en) Prophylactic or therapeutic drug for neurodegenerative diseases
CN101268093B (zh) Age抑制剂
CA3199088A1 (en) Respiratory treatments
MX2011013311A (es) Propiedades neuroprotectoras de 5'-metiltioadenosina.
JP2002527350A (ja) 発作を治療するのに有用なアミノ酸誘導体
EP3341739A1 (en) Mutant peptides and methods of treating subjects using the same
JP2011231022A (ja) イミダゾロン誘導体
JP2004002231A (ja) ルブロフサリン配糖体含有組成物
FI109026B (fi) Menetelmä uusien immuunivastetta heikentävien trans-syklopentanyylipuriinianalogien valmistamiseksi
RU2396076C1 (ru) Средство, уменьшающее степень острой алкогольной интоксикации (опьянения) и обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
JP5222608B2 (ja) 抗不安作用剤
CA3212092A1 (en) Compositions and methods for treating neurologic diseases
WO2017017585A1 (en) Compound, composition and uses thereof
US12139505B2 (en) Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same
US20250108038A1 (en) Substituted derivatives of isoindoles and uses thereof
JPH09509158A (ja) エンケファリナーゼ及びａｃｅの阻害剤として有用な、新規なメルカプトアセチルアミドジスルフィド誘導体類
TWI705059B (zh) 法尼基轉移酶抑制劑及其用途
WO2014060942A2 (en) Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
JPS6248633A (ja) 抗アレルギ−剤及び気管支拡張剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241115

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250923